This developed qPCR assay shows high specificity in detection of the LMP1 30 bp deletion genetic biomarker among NPC patients, where this assay is capable of differentiating between MT and WT variants in NPC samples and is able to distinguish NPC from among both non-NPC cancer and healthy individuals. This evidence concerns the gene PDLIM7 and cancer.